Osteoporosis

Fractures resulting from osteoporosis are a major public health problem. Physicians should be aware of the chief risk factors for osteoporosis and refer appropriately for bone densitometry. Risk factors include previous fracture, a family history of fracture, slender habitus, early menopause, treatment with drugs known to affect bone (glucocorticoids) and diseases known to affect bone (rheumatoid arthritis). The diagnosis of osteoporosis can be made if the bone density T-score is −2.5 or below. This information can be used with other risk factors to estimate the 10-year risk of fractures. Patients at the highest risk for fracture benefit from many licensed treatments. These may be given orally (alendronic acid, disodium etidronate, risedronate sodium, ibandronic acid, strontium ranelate, calcitriol, raloxifene, hormone replacement therapy), subcutaneously (calcitonin, parathyroid hormone, denosumab) or intravenously (ibandronic acid, zoledronic acid) and usually result in an increase in bone mineral density and a reduction in fracture risk.